clinical trial data

Disc Medicine to present Phase 2 DISC-0974 data showing unprecedented anemia response rates in myelofibrosis at ASCO 2026, potentially reshaping treatment landscape.

Kura Oncology reports darlifarnib plus cabozantinib achieved 44% response rate in cabozantinib-pretreated renal cell carcinoma patients, potentially overcoming drug resistance.

Aldeyra Therapeutics faces securities fraud lawsuit alleging it concealed reproxalap trial data inconsistencies, leading to 70.7% stock collapse after FDA rejection in March 2026.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.

Aldeyra Therapeutics faces securities fraud lawsuit alleging hidden trial data; stock collapsed 71% after FDA's adverse decision on reproxalap.

Sagimet presented Phase 2b denifanstat data showing bile acid biomarker potential in MASH patients, while securing Nasdaq approval for employee stock options.

Major selloff hit large-cap stocks during shortened week, with Nike down 14.29%, Boston Scientific down 9.32%, and Sysco down 13.56% amid guidance misses and analyst downgrades.

ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.

uniQure shares collapsed 49% after FDA signaled Phase I/II data insufficient for AMT-130 approval, prompting investors to file class action lawsuit.

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.

Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.

Class action lawsuit filed against $VTGN alleges securities fraud over misleading statements about fasedienol drug candidate and PALISADE-3 clinical trial data.

Rhythm Pharmaceuticals reports positive Phase 3 data for setmelanotide treating acquired hypothalamic obesity, with FDA decision expected March 2026.